Bone densitometry

a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment

Pernille Ravn, P Alexandersen, A Møllgaard

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The bisphosphonates have been introduced as alternatives to hormone replacement therapy (HRT) for the treatment and prevention of postmenopausal osteoporosis. The expected increasing application in at clinical practice demands cost-effective and easily handled methods to monitor the effect on bone. The weak response at the distal forearm during antiresorptive treatment has restricted the use of bone densitometry at this region. We describe a new model for bone densitometry at the distal forearm, by which the response obtained is comparable to the response in other regions where bone densitometry is much more expensive and technically complicated. By computerized iteration of single X-ray absorptiometry forearm scans we defined a region with 65% trabecular bone. The region was analyzed in randomized, double-masked, placebo- controlled trials: a 2-year trial with alendronate (n = 69), a 1-year trial with ibandronate (n = 141) and a 2-year trial with HRT (n = 121). Bone mineral density (BMD) at the distal forearm revealed a highly statistically significant dose-related response and increased 3-5% per year with 2.5 mg ibandronate, 10 mg alendronate or HRT, whereas the decrease in the placebo groups was 1-3% (p<0.001). The response at the distal forearm was similar to the response at the lumbar spine and hip. In conclusion, trabecular bone at the distal forearm is as responsive to antiresorptive treatment as trabecular bone in other skeletal regions. Bone densitometry at the new region of interest in the distal forearm has comparable performance characteristics to more expensive and technically demanding methods. The method is more accessible clinically and has potential as an alternative for monitoring bone mass changes during antiresorptive treatment.

OriginalsprogEngelsk
TidsskriftOsteoporosis International
Vol/bind9
Udgave nummer4
Sider (fra-til)277-83
Antal sider7
ISSN0937-941X
DOI
StatusUdgivet - 1999

Fingeraftryk

Densitometry
Forearm
Alendronate
Placebos
Postmenopausal Osteoporosis
Photon Absorptiometry
Bone Density
Hip
Cancellous Bone

Citer dette

@article{33dbcd03fb3442098747236c32b7da53,
title = "Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment",
abstract = "The bisphosphonates have been introduced as alternatives to hormone replacement therapy (HRT) for the treatment and prevention of postmenopausal osteoporosis. The expected increasing application in at clinical practice demands cost-effective and easily handled methods to monitor the effect on bone. The weak response at the distal forearm during antiresorptive treatment has restricted the use of bone densitometry at this region. We describe a new model for bone densitometry at the distal forearm, by which the response obtained is comparable to the response in other regions where bone densitometry is much more expensive and technically complicated. By computerized iteration of single X-ray absorptiometry forearm scans we defined a region with 65{\%} trabecular bone. The region was analyzed in randomized, double-masked, placebo- controlled trials: a 2-year trial with alendronate (n = 69), a 1-year trial with ibandronate (n = 141) and a 2-year trial with HRT (n = 121). Bone mineral density (BMD) at the distal forearm revealed a highly statistically significant dose-related response and increased 3-5{\%} per year with 2.5 mg ibandronate, 10 mg alendronate or HRT, whereas the decrease in the placebo groups was 1-3{\%} (p<0.001). The response at the distal forearm was similar to the response at the lumbar spine and hip. In conclusion, trabecular bone at the distal forearm is as responsive to antiresorptive treatment as trabecular bone in other skeletal regions. Bone densitometry at the new region of interest in the distal forearm has comparable performance characteristics to more expensive and technically demanding methods. The method is more accessible clinically and has potential as an alternative for monitoring bone mass changes during antiresorptive treatment.",
keywords = "Absorptiometry, Photon, Adult, Aged, Alendronate, Analysis of Variance, Bone Resorption, Diphosphonates, Dose-Response Relationship, Drug, Double-Blind Method, Estrogen Replacement Therapy, Female, Humans, Image Processing, Computer-Assisted, Linear Models, Male, Middle Aged, Osteoporosis, Postmenopausal, Radius, Sensitivity and Specificity, Ulna",
author = "Pernille Ravn and P Alexandersen and A M{\o}llgaard",
year = "1999",
doi = "10.1007/s001980050148",
language = "English",
volume = "9",
pages = "277--83",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer",
number = "4",

}

Bone densitometry : a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment. / Ravn, Pernille; Alexandersen, P; Møllgaard, A.

I: Osteoporosis International, Bind 9, Nr. 4, 1999, s. 277-83.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Bone densitometry

T2 - a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment

AU - Ravn, Pernille

AU - Alexandersen, P

AU - Møllgaard, A

PY - 1999

Y1 - 1999

N2 - The bisphosphonates have been introduced as alternatives to hormone replacement therapy (HRT) for the treatment and prevention of postmenopausal osteoporosis. The expected increasing application in at clinical practice demands cost-effective and easily handled methods to monitor the effect on bone. The weak response at the distal forearm during antiresorptive treatment has restricted the use of bone densitometry at this region. We describe a new model for bone densitometry at the distal forearm, by which the response obtained is comparable to the response in other regions where bone densitometry is much more expensive and technically complicated. By computerized iteration of single X-ray absorptiometry forearm scans we defined a region with 65% trabecular bone. The region was analyzed in randomized, double-masked, placebo- controlled trials: a 2-year trial with alendronate (n = 69), a 1-year trial with ibandronate (n = 141) and a 2-year trial with HRT (n = 121). Bone mineral density (BMD) at the distal forearm revealed a highly statistically significant dose-related response and increased 3-5% per year with 2.5 mg ibandronate, 10 mg alendronate or HRT, whereas the decrease in the placebo groups was 1-3% (p<0.001). The response at the distal forearm was similar to the response at the lumbar spine and hip. In conclusion, trabecular bone at the distal forearm is as responsive to antiresorptive treatment as trabecular bone in other skeletal regions. Bone densitometry at the new region of interest in the distal forearm has comparable performance characteristics to more expensive and technically demanding methods. The method is more accessible clinically and has potential as an alternative for monitoring bone mass changes during antiresorptive treatment.

AB - The bisphosphonates have been introduced as alternatives to hormone replacement therapy (HRT) for the treatment and prevention of postmenopausal osteoporosis. The expected increasing application in at clinical practice demands cost-effective and easily handled methods to monitor the effect on bone. The weak response at the distal forearm during antiresorptive treatment has restricted the use of bone densitometry at this region. We describe a new model for bone densitometry at the distal forearm, by which the response obtained is comparable to the response in other regions where bone densitometry is much more expensive and technically complicated. By computerized iteration of single X-ray absorptiometry forearm scans we defined a region with 65% trabecular bone. The region was analyzed in randomized, double-masked, placebo- controlled trials: a 2-year trial with alendronate (n = 69), a 1-year trial with ibandronate (n = 141) and a 2-year trial with HRT (n = 121). Bone mineral density (BMD) at the distal forearm revealed a highly statistically significant dose-related response and increased 3-5% per year with 2.5 mg ibandronate, 10 mg alendronate or HRT, whereas the decrease in the placebo groups was 1-3% (p<0.001). The response at the distal forearm was similar to the response at the lumbar spine and hip. In conclusion, trabecular bone at the distal forearm is as responsive to antiresorptive treatment as trabecular bone in other skeletal regions. Bone densitometry at the new region of interest in the distal forearm has comparable performance characteristics to more expensive and technically demanding methods. The method is more accessible clinically and has potential as an alternative for monitoring bone mass changes during antiresorptive treatment.

KW - Absorptiometry, Photon

KW - Adult

KW - Aged

KW - Alendronate

KW - Analysis of Variance

KW - Bone Resorption

KW - Diphosphonates

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Estrogen Replacement Therapy

KW - Female

KW - Humans

KW - Image Processing, Computer-Assisted

KW - Linear Models

KW - Male

KW - Middle Aged

KW - Osteoporosis, Postmenopausal

KW - Radius

KW - Sensitivity and Specificity

KW - Ulna

U2 - 10.1007/s001980050148

DO - 10.1007/s001980050148

M3 - Journal article

VL - 9

SP - 277

EP - 283

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 4

ER -